CL2017001972A1 - Biomarcadores para cáncer pancreático - Google Patents

Biomarcadores para cáncer pancreático

Info

Publication number
CL2017001972A1
CL2017001972A1 CL2017001972A CL2017001972A CL2017001972A1 CL 2017001972 A1 CL2017001972 A1 CL 2017001972A1 CL 2017001972 A CL2017001972 A CL 2017001972A CL 2017001972 A CL2017001972 A CL 2017001972A CL 2017001972 A1 CL2017001972 A1 CL 2017001972A1
Authority
CL
Chile
Prior art keywords
biomarkers
pancreatic cancer
pancreatic
diagnosis
adenocarcinoma
Prior art date
Application number
CL2017001972A
Other languages
English (en)
Inventor
Tatjana Crnogorac-Jurcevic
Tomasz Radon
Original Assignee
Univ London Queen Mary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London Queen Mary filed Critical Univ London Queen Mary
Publication of CL2017001972A1 publication Critical patent/CL2017001972A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A CÁNCERES PANCREÁTICOS Y EL USO DE BIOMARCADORES EN MUESTRAS BIOLÓGICAS PARA EL DIAGNÓSTICO DE TALES CONDICIONES, EN PARTICULAR ADENOCARCINOMA DUCTAL PANCREÁTICO. EL PANEL DE BIOMARCADORES COMPRENDE LYVE1, REG1 Y TFF1. MÉTODOS DE TRATAMIENTO TAMBIÉN SON PROPORCIONADOS, ASÍ COMO TAMBIÉN KITS ÚTILES EN EL DIAGNÓSTICO Y TRATAMIENTO DE ADENOCARCINOMA DUCTAL PANCREÁTICO. LA PRESENTE INVENCIÓN ES PARTICULARMENTE ÚTIL EN DETECTAR PDAC EN ESTADIO TEMPRANO.</p>
CL2017001972A 2015-02-05 2017-08-02 Biomarcadores para cáncer pancreático CL2017001972A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1501930.0A GB201501930D0 (en) 2015-02-05 2015-02-05 Biomarkers for pancreatic cancer

Publications (1)

Publication Number Publication Date
CL2017001972A1 true CL2017001972A1 (es) 2018-03-23

Family

ID=52746188

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001972A CL2017001972A1 (es) 2015-02-05 2017-08-02 Biomarcadores para cáncer pancreático

Country Status (15)

Country Link
US (2) US10782301B2 (es)
EP (1) EP3254111A1 (es)
JP (1) JP6786499B2 (es)
KR (1) KR102569984B1 (es)
CN (1) CN107533062B (es)
AU (1) AU2016214140B2 (es)
BR (1) BR112017016808A2 (es)
CA (1) CA2974775C (es)
CL (1) CL2017001972A1 (es)
GB (1) GB201501930D0 (es)
HK (1) HK1247276A1 (es)
IL (1) IL253710B (es)
MX (1) MX2017009998A (es)
SG (1) SG11201706223VA (es)
WO (1) WO2016124947A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
GB201501930D0 (en) * 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CN107674884A (zh) * 2017-09-05 2018-02-09 上海速创诊断产品有限公司 一种用于检测胰腺癌标记物reg1a的生物素化脂质体及其制备方法和应用
TWI643869B (zh) * 2017-12-14 2018-12-11 國立高雄大學 Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof
US20210052231A1 (en) * 2017-12-14 2021-02-25 Salcit Technologies Private Limited Method and system for analyzing risk associated with respiratory sounds
KR102000387B1 (ko) * 2018-02-13 2019-07-15 서울대학교산학협력단 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CN109358055A (zh) * 2018-12-18 2019-02-19 沈阳理工大学 增敏测定空气中氨的混合指示剂试纸及其制备和检测方法
CN111303281A (zh) * 2019-05-14 2020-06-19 长春恒晓生物科技有限责任公司 制备胰石蛋白抗体及建立检测psp方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
JP4679149B2 (ja) * 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 ヒト膵癌に関連する遺伝子およびポリペプチド
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050095611A1 (en) 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
EP1673623A1 (en) 2003-05-15 2006-06-28 Europroteome AG Methods and applications of biomarker profiles in the diagnosis and treatment of breast cancer
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
CA2595377A1 (en) 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
ATE555215T1 (de) 2005-06-27 2012-05-15 Wayne John Cancer Inst Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert
WO2007035684A2 (en) 2005-09-16 2007-03-29 Primera Biosystems, Inc. Method for quantitative detection of short rna molecules
EP2591794A1 (en) 2006-01-05 2013-05-15 The Ohio State University Research Foundation MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
CA2642833A1 (en) 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008042435A2 (en) * 2006-10-03 2008-04-10 Neuren Pharmaceuticals Limited Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20100144850A1 (en) 2007-04-30 2010-06-10 The Ohio State University Research Foundation Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis
DK2294215T3 (da) * 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
US20090304700A1 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals, Ltd. Conformation specific antibodies that bind trefoil factors
JP2012100536A (ja) * 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
CA2787074A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011137288A2 (en) 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US20140235494A1 (en) * 2011-09-21 2014-08-21 The Universify of North Carolina at Chapel Hill Methods, Kits and Computer Program Products using Hepatocellular Carcinoma (HCC) Biomarkers
DE102012204366B4 (de) 2011-12-16 2017-07-27 Siemens Aktiengesellschaft Verfahren und Kit zur Identifizierung und Quantifizierung von einer einzelsträngigen Ziel-Nukleinsäure
WO2013106844A2 (en) * 2012-01-13 2013-07-18 Oncocyte Corporation Methods and compositions for the treatment and diaginosis of pancreatic cancer
EP2804958A2 (en) 2012-01-16 2014-11-26 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20130216545A1 (en) * 2012-02-19 2013-08-22 Claresa Levetan Early Diagnosis and Novel Treatment of Cancer
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140271621A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
US20150018230A1 (en) 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer

Also Published As

Publication number Publication date
AU2016214140A1 (en) 2017-08-17
IL253710A0 (en) 2017-09-28
BR112017016808A2 (pt) 2018-04-03
US10782301B2 (en) 2020-09-22
KR20170129118A (ko) 2017-11-24
CA2974775A1 (en) 2016-08-11
GB201501930D0 (en) 2015-03-25
SG11201706223VA (en) 2017-08-30
AU2016214140B2 (en) 2021-11-04
WO2016124947A1 (en) 2016-08-11
US20190204323A1 (en) 2019-07-04
EP3254111A1 (en) 2017-12-13
HK1247276A1 (zh) 2018-09-21
KR102569984B1 (ko) 2023-08-22
JP2018504609A (ja) 2018-02-15
JP6786499B2 (ja) 2020-11-18
US20220042998A1 (en) 2022-02-10
IL253710B (en) 2020-08-31
MX2017009998A (es) 2018-02-01
CN107533062B (zh) 2021-03-23
CA2974775C (en) 2023-11-07
CN107533062A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
CL2017001972A1 (es) Biomarcadores para cáncer pancreático
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2020004567A (es) Metodos diagnosticos y terapeuticos para el cancer.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l&#39;expression de hgf
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
BR112013004673A2 (pt) biomarcadores e métodos de tratamento.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
MX2013005067A (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
WO2015171736A3 (en) Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
MX2018013621A (es) Metodo, matriz y uso de estos.
MX2019008911A (es) Metodos, matrices y usos de estos.
IL269552A (en) Diagnostic methods and kits for early detection of ovarian cancer
NZ729773A (en) Biomarkers for disease progression in melanoma
MA40636A (fr) Procédés pour détecter le cancer de la prostate
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
EA201590495A1 (ru) Способ диагностики и лечения рака, направленный на молекулы, экспрессируемые в раковых стволовых клетках